[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 20, 2005

Erythropoietin and Cancer

JAMA. 2005;293(15):1858-1859. doi:10.1001/jama.293.15.1858-a

To the Editor: The Contempo Update by Dr Maiese and colleagues1 presents new avenues of exploration for erythropoietin. It provides evidence that would support the concept that erythropoietin, approved by the US Food and Drug Administration for the treatment of anemia associated with cancer chemotherapy, may not be appropriate for this indication. If erythropoietin is truly proangiogenic and antiapoptotic, as the authors suggest, the administration of this agent to patients with cancer would seem ill-advised. A recent report suggesting that erythropoietin may impair survival in patients with head and neck cancer2 is further cause for concern for many oncologists who prescribe the drug rather routinely. Although erythropoietin may hold promise for the treatment of cardiovascular and cerebrovascular disease in the future, I believe that its current widespread use in patients with cancer is open to serious question.

First Page Preview View Large
First page PDF preview
First page PDF preview
×